Dose-dependent levels of epigallocatechin-3-gallate in human colon cancer cells and mouse plasma and tissues

Joshua D. Lambert, Mao Jung Lee, Lauren Diamond, Jihyeung Ju, Jungil Hong, Mousumi Bose, Harold L. Newmark, Chung S. Yang

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

Epigallocatechin-3-gallate (EGCG; molecular formula: C22H 18011) is the most abundant catechin in green tea (Camellia sinensis Theaceae). Both EGCG and green tea have been shown to have cancer-preventive activity in a number of animal models, and numerous mechanisms have been proposed based on studies with human cell lines. EGCG has been shown to undergo extensive biotransformation to yield methylated and glucuronidated metabolites in mice, rats, and humans. In the present study, we determined the concentration-dependent uptake of EGCG by HT-29 human colon cancer cells (20-600 μM) and the dose dependence of EGCG plasma and tissue levels after a single dose of EGCG (50-2000 mg/kg i.g.) to male CF-1 mice. The cytosolic levels of EGCG were linear with respect to extracellular concentration of EGCG after treatment of HT-29 cells for 2 h (915.3-6851.6 μg/g). In vivo, EGCG exhibited a linear dose relationship in the plasma (0.03-4.17 μg/ml), prostate (0.01-0.91 μg/g), and liver (0.09- 18.3 μg/g). In the small intestine and colon, however, the levels of EGCG plateaued between 500 and 2000 mg/kg i.g. These results suggest that absorption of EGCG from the small intestine is largely via passive diffusion; however, at high concentrations, the small intestinal and colonic tissues become saturated. The levels of 4″-O-methyl-EGCG and 4′,4″-di-O-methyl-EGCG parallel those of EGCG with respect to dose. The present study provides information with respect to what concentrations of EGCG are achievable in mice and may guide dose selection for future cancer chemoprevention studies with EGCG.

Original languageEnglish (US)
Pages (from-to)8-11
Number of pages4
JournalDrug Metabolism and Disposition
Volume34
Issue number1
DOIs
StatePublished - Jan 1 2006

Fingerprint

Theaceae
Plasma Cells
Camellia sinensis
Colonic Neoplasms
Small Intestine
HT29 Cells
Catechin
Chemoprevention
Biotransformation
Prostate
Neoplasms
Colon
Animal Models
Cell Line
Liver
epigallocatechin gallate
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science

Cite this

Lambert, Joshua D. ; Lee, Mao Jung ; Diamond, Lauren ; Ju, Jihyeung ; Hong, Jungil ; Bose, Mousumi ; Newmark, Harold L. ; Yang, Chung S. / Dose-dependent levels of epigallocatechin-3-gallate in human colon cancer cells and mouse plasma and tissues. In: Drug Metabolism and Disposition. 2006 ; Vol. 34, No. 1. pp. 8-11.
@article{7b945342e098470c9d1bf50c434247ff,
title = "Dose-dependent levels of epigallocatechin-3-gallate in human colon cancer cells and mouse plasma and tissues",
abstract = "Epigallocatechin-3-gallate (EGCG; molecular formula: C22H 18011) is the most abundant catechin in green tea (Camellia sinensis Theaceae). Both EGCG and green tea have been shown to have cancer-preventive activity in a number of animal models, and numerous mechanisms have been proposed based on studies with human cell lines. EGCG has been shown to undergo extensive biotransformation to yield methylated and glucuronidated metabolites in mice, rats, and humans. In the present study, we determined the concentration-dependent uptake of EGCG by HT-29 human colon cancer cells (20-600 μM) and the dose dependence of EGCG plasma and tissue levels after a single dose of EGCG (50-2000 mg/kg i.g.) to male CF-1 mice. The cytosolic levels of EGCG were linear with respect to extracellular concentration of EGCG after treatment of HT-29 cells for 2 h (915.3-6851.6 μg/g). In vivo, EGCG exhibited a linear dose relationship in the plasma (0.03-4.17 μg/ml), prostate (0.01-0.91 μg/g), and liver (0.09- 18.3 μg/g). In the small intestine and colon, however, the levels of EGCG plateaued between 500 and 2000 mg/kg i.g. These results suggest that absorption of EGCG from the small intestine is largely via passive diffusion; however, at high concentrations, the small intestinal and colonic tissues become saturated. The levels of 4″-O-methyl-EGCG and 4′,4″-di-O-methyl-EGCG parallel those of EGCG with respect to dose. The present study provides information with respect to what concentrations of EGCG are achievable in mice and may guide dose selection for future cancer chemoprevention studies with EGCG.",
author = "Lambert, {Joshua D.} and Lee, {Mao Jung} and Lauren Diamond and Jihyeung Ju and Jungil Hong and Mousumi Bose and Newmark, {Harold L.} and Yang, {Chung S.}",
year = "2006",
month = "1",
day = "1",
doi = "10.1124/dmd.104.003434",
language = "English (US)",
volume = "34",
pages = "8--11",
journal = "Drug Metabolism and Disposition",
issn = "0090-9556",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

Dose-dependent levels of epigallocatechin-3-gallate in human colon cancer cells and mouse plasma and tissues. / Lambert, Joshua D.; Lee, Mao Jung; Diamond, Lauren; Ju, Jihyeung; Hong, Jungil; Bose, Mousumi; Newmark, Harold L.; Yang, Chung S.

In: Drug Metabolism and Disposition, Vol. 34, No. 1, 01.01.2006, p. 8-11.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Dose-dependent levels of epigallocatechin-3-gallate in human colon cancer cells and mouse plasma and tissues

AU - Lambert, Joshua D.

AU - Lee, Mao Jung

AU - Diamond, Lauren

AU - Ju, Jihyeung

AU - Hong, Jungil

AU - Bose, Mousumi

AU - Newmark, Harold L.

AU - Yang, Chung S.

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Epigallocatechin-3-gallate (EGCG; molecular formula: C22H 18011) is the most abundant catechin in green tea (Camellia sinensis Theaceae). Both EGCG and green tea have been shown to have cancer-preventive activity in a number of animal models, and numerous mechanisms have been proposed based on studies with human cell lines. EGCG has been shown to undergo extensive biotransformation to yield methylated and glucuronidated metabolites in mice, rats, and humans. In the present study, we determined the concentration-dependent uptake of EGCG by HT-29 human colon cancer cells (20-600 μM) and the dose dependence of EGCG plasma and tissue levels after a single dose of EGCG (50-2000 mg/kg i.g.) to male CF-1 mice. The cytosolic levels of EGCG were linear with respect to extracellular concentration of EGCG after treatment of HT-29 cells for 2 h (915.3-6851.6 μg/g). In vivo, EGCG exhibited a linear dose relationship in the plasma (0.03-4.17 μg/ml), prostate (0.01-0.91 μg/g), and liver (0.09- 18.3 μg/g). In the small intestine and colon, however, the levels of EGCG plateaued between 500 and 2000 mg/kg i.g. These results suggest that absorption of EGCG from the small intestine is largely via passive diffusion; however, at high concentrations, the small intestinal and colonic tissues become saturated. The levels of 4″-O-methyl-EGCG and 4′,4″-di-O-methyl-EGCG parallel those of EGCG with respect to dose. The present study provides information with respect to what concentrations of EGCG are achievable in mice and may guide dose selection for future cancer chemoprevention studies with EGCG.

AB - Epigallocatechin-3-gallate (EGCG; molecular formula: C22H 18011) is the most abundant catechin in green tea (Camellia sinensis Theaceae). Both EGCG and green tea have been shown to have cancer-preventive activity in a number of animal models, and numerous mechanisms have been proposed based on studies with human cell lines. EGCG has been shown to undergo extensive biotransformation to yield methylated and glucuronidated metabolites in mice, rats, and humans. In the present study, we determined the concentration-dependent uptake of EGCG by HT-29 human colon cancer cells (20-600 μM) and the dose dependence of EGCG plasma and tissue levels after a single dose of EGCG (50-2000 mg/kg i.g.) to male CF-1 mice. The cytosolic levels of EGCG were linear with respect to extracellular concentration of EGCG after treatment of HT-29 cells for 2 h (915.3-6851.6 μg/g). In vivo, EGCG exhibited a linear dose relationship in the plasma (0.03-4.17 μg/ml), prostate (0.01-0.91 μg/g), and liver (0.09- 18.3 μg/g). In the small intestine and colon, however, the levels of EGCG plateaued between 500 and 2000 mg/kg i.g. These results suggest that absorption of EGCG from the small intestine is largely via passive diffusion; however, at high concentrations, the small intestinal and colonic tissues become saturated. The levels of 4″-O-methyl-EGCG and 4′,4″-di-O-methyl-EGCG parallel those of EGCG with respect to dose. The present study provides information with respect to what concentrations of EGCG are achievable in mice and may guide dose selection for future cancer chemoprevention studies with EGCG.

UR - http://www.scopus.com/inward/record.url?scp=29944437798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29944437798&partnerID=8YFLogxK

U2 - 10.1124/dmd.104.003434

DO - 10.1124/dmd.104.003434

M3 - Article

C2 - 16204466

AN - SCOPUS:29944437798

VL - 34

SP - 8

EP - 11

JO - Drug Metabolism and Disposition

JF - Drug Metabolism and Disposition

SN - 0090-9556

IS - 1

ER -